Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment

doi:10.1038/s41416-019-0681-5

Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment

科研成果: 期刊稿件 › 文章 › 同行评审

源语言	英语
页（从-至）	517-527
页数	11
期刊	British Journal of Cancer
卷	122
期	4
DOI	https://doi.org/10.1038/s41416-019-0681-5
出版状态	已出版 - 2月 18 2020
已对外发布	是

!!!ASJC Scopus Subject Areas

肿瘤学
癌症研究

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1038/s41416-019-0681-5

其它文件与链接

引用此

@article{76931b70bad04467b2647b355ecfede0,

title = "Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2020",

month = feb,

day = "18",

doi = "10.1038/s41416-019-0681-5",

language = "English",

volume = "122",

pages = "517--527",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment

PY - 2020/2/18

Y1 - 2020/2/18

UR - http://www.scopus.com/inward/record.url?scp=85076468072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076468072&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0681-5

DO - 10.1038/s41416-019-0681-5

M3 - Article

C2 - 31844184

AN - SCOPUS:85076468072

SN - 0007-0920

VL - 122

SP - 517

EP - 527

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 4

ER -

Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此